Key facts
- INCY - INCYTE CORP has 38 insiders with reported activity on this page.
- Net insider value flow over the last year: -$43,303,297.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 38 Insiders of INCYTE CORP
- Symbol
- INCY on Nasdaq
- Location
- Wilmington, DE
Change
- Buy value: ; sell value: $43,303,297.
- Net share flow: -442,242.
Research use
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$43,303,297.
Buys
$0
Shares: 0
Insiders: 0
Sells
$43,303,297
Shares: 442,242
Insiders: 12
Net
-$43,303,297
Shares: -442,242
Insiders: -12
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 52,334 | $0 | $4,984,494 | -$4,984,494 |
| 3-6 | 0 | 135,335 | $0 | $13,548,585 | -$13,548,585 |
| 6-9 | 0 | 202,705 | $0 | $21,215,730 | -$21,215,730 |
| 9-12 | 0 | 51,868 | $0 | $3,554,489 | -$3,554,489 |
INCYTE CORP executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Julian C. Baker | Director, 10%+ Owner | $2,680,999,540 | Median | 08 May 2026 | ||
| 667, L.P. | Director, 10%+ Owner | $2,680,999,540 | Median | 08 May 2026 | ||
| Baker Bros. Advisors (GP) LLC | Director, 10%+ Owner | $2,680,999,540 | Median | 08 May 2026 | ||
| Felix Baker | Director, 10%+ Owner | $2,680,999,540 | Median | 08 May 2026 | ||
| BAKER BROS. ADVISORS LP | Director, 10%+ Owner | $2,680,999,540 | Median | 08 May 2026 | ||
| Baker Brothers Life Sciences LP | Director, 10%+ Owner | $2,680,999,540 | Median | 08 May 2026 | ||
| Herve Hoppenot | Director | $31,601,850 | -$19,773,750 | -38% | Mixed | 08 Dec 2025 |
| Pablo J. Cagnoni | President, Global Head of R&D | $25,065,756 | -$5,444,331 | -18% | Median | 06 May 2026 |
| William Meury | Chief Executive Officer, Director, President | $15,162,826 | Median | 15 Apr 2026 | ||
| Christiana Stamoulis | EVP & Chief Financial Officer | $8,564,187 | Mixed | 14 Jul 2025 | ||
| Steven H. Stein | CMO & Head of Late-Stage Dev. | $7,372,137 | -$5,724,778 | -44% | Median | 06 May 2026 |
| Paula J. Swain | EVP, Human Resources | $7,251,424 | Mixed | 14 Jul 2025 | ||
| Mohamed Khairie Issa | EVP, Head of US Oncology | $7,213,017 | -$1,184,064 | -14% | Filing P/S | 16 Jan 2026 |
| Wenqing Yao | EVP, Head of Discovery Chem | $6,062,363 | Mixed | 02 Jul 2021 | ||
| Patrick A. Mayes | EVP & Chief Scientific Officer | $5,697,444 | -$554,965 | -8.9% | Filing P/S | 16 Jan 2026 |
| Maria E. Pasquale | EVP & General Counsel | $4,288,026 | Mixed | 14 Jul 2023 | ||
| Lee Heeson | EVP, Head of Incyte Intl | $3,905,669 | -$289,017 | -6.9% | Mixed | 02 Feb 2026 |
| Dashyant Dhanak | EVP & Chief Scientific Officer | $3,626,532 | Mixed | 14 Jul 2023 | ||
| Michael James Morrissey | EVP, Head of Tech. Operations | $3,497,453 | -$5,675,002 | -62% | Mixed | 02 Feb 2026 |
| Sheila A. Denton | EVP & General Counsel | $2,772,740 | -$1,057,923 | -28% | Filing P/S | 17 Nov 2025 |
| Vijay K. Iyengar | Evp, Gmapps | $2,771,314 | -$736,698 | -21% | Filing P/S | 16 Jul 2025 |
| Suketu Upadhyay | EVP & Chief Financial Officer | $2,479,403 | Median | 04 May 2026 | ||
| Barry P. Flannelly | EVP & General Manager US | $2,402,785 | -$917,915 | -28% | Filing P/S | 16 Jul 2025 |
| Thomas Tray | Principal Accounting Officer | $2,297,300 | -$520,904 | -18% | Filing P/S | 16 Jan 2026 |
| Jonathan Elliott Dickinson | EVP, General Manager, Europe | $2,269,644 | Filing P/S | 12 Sep 2024 | ||
| Paul J. Clancy | Director | $2,253,733 | -$1,423,950 | -39% | Filing P/S | 19 May 2026 |
| Edmund Harrigan | Director | $2,086,219 | Mixed | 31 Mar 2026 | ||
| Matteo Trotta | EVP, GM, Dermatology US | $1,469,895 | Mixed | 25 Mar 2026 | ||
| Jean J. Bienaime | Director | $1,268,174 | Mixed | 10 Jun 2025 | ||
| Jacqualyn A. Fouse | Director | $1,175,987 | Mixed | 10 Jun 2025 | ||
| Wendy L. Dixon | Director | $1,092,732 | Mixed | 31 Mar 2022 | ||
| Richard A. Hoffman | EVP & General Counsel | $997,811 | Mixed | 01 Dec 2025 | ||
| Katherine A. High | Director | $811,799 | Mixed | 10 Jun 2025 | ||
| David H. Gardner | EVP, Chief Strategy Officer | $789,207 | Mixed | 22 Sep 2025 | ||
| Dr. Otis W. Brawley | Director | $684,684 | Mixed | 10 Jun 2025 | ||
| Ramitpal K. Basi | EVP, Human Resources | $456,460 | Mixed | 25 Aug 2025 | ||
| Susanne Schaffert | Director | $449,620 | Mixed | 10 Jun 2025 | ||
| Paul Trower | Principal Accounting Officer | Mixed | 19 Jan 2022 |
Top shareholders of INCYTE CORP (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP |
13D/G
3/4/5
13F
|
Felix J. Baker · Director, 10%+ Owner · Company |
16%
|
31,225,572
|
$3,027,631,461 | +$1,178,549 | 07 May 2026 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
7.8%
from 13D/G
|
18,978,198
|
$1,786,227,957 | — | 31 Mar 2026 | |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
|
Vanguard Capital Management · Company |
6.3%
|
12,591,630
|
$1,185,124,216 | $0 | 31 Mar 2026 | |
| DODGE & COX |
13D/G
13F
|
Company |
6.2%
|
12,252,356
|
$1,187,988,438 | $0 | 31 Mar 2026 | |
| STATE STREET CORP |
13F
13D/G
|
Company · STATE STREET CORPORATION |
5%
from 13D/G
|
9,641,384
|
$907,447,062 | — | 31 Mar 2026 | |
| 667, L.P. |
3/4/5
|
Director, 10%+ Owner |
14%
|
28,484,908
|
$2,680,999,540 | — | 08 May 2026 | |
| Baker Bros. Advisors (GP) LLC |
3/4/5
|
Director, 10%+ Owner |
14%
|
28,484,908
|
$2,680,999,540 | — | 08 May 2026 | |
| Baker Brothers Life Sciences LP |
3/4/5
|
Director, 10%+ Owner |
14%
|
28,484,908
|
$2,680,999,540 | — | 08 May 2026 | |
| Felix Baker |
3/4/5
|
Director, 10%+ Owner |
14%
|
28,484,908
|
$2,680,999,540 | — | 08 May 2026 | |
| Julian C. Baker |
3/4/5
|
Director, 10%+ Owner |
14%
|
28,484,908
|
$2,680,999,540 | — | 08 May 2026 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13F
|
Company |
3.9%
|
7,759,183
|
$730,294,304 | — | 31 Mar 2026 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
2.9%
|
5,807,930
|
$536,130,025 | — | 31 Mar 2026 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.4%
|
4,703,184
|
$441,081,113 | — | 31 Mar 2026 | |
| LSV ASSET MANAGEMENT |
13F
|
Company |
2%
|
3,920,056
|
$368,956,000 | — | 31 Mar 2026 | |
| Invesco Ltd. |
13F
|
Company |
2%
|
3,870,764
|
$364,316,308 | — | 31 Mar 2026 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
1.8%
|
3,651,532
|
$343,682,192 | — | 31 Mar 2026 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
1.7%
|
3,266,136
|
$307,408,721 | — | 31 Mar 2026 | |
| MORGAN STANLEY |
13F
|
Company |
1.4%
|
2,850,328
|
$268,272,995 | — | 31 Mar 2026 | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP |
13F
|
Company |
1.4%
|
2,830,799
|
$266,434,802 | — | 31 Mar 2026 | |
| Robeco Institutional Asset Management B.V. |
13F
|
Company |
1.3%
|
2,514,383
|
$236,653,725 | — | 31 Mar 2026 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.2%
|
2,351,221
|
$221,296,953 | — | 31 Mar 2026 | |
| LOS ANGELES CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.1%
|
2,144,847
|
$201,873,001 | — | 31 Mar 2026 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1%
|
1,975,544
|
$185,872,809 | — | 31 Mar 2026 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.96%
|
1,900,824
|
$178,867,000 | — | 31 Mar 2026 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.94%
|
1,849,726
|
$174,096,211 | — | 31 Mar 2026 | |
| VICTORY CAPITAL MANAGEMENT INC |
13F
|
Company |
0.88%
|
1,742,870
|
$164,038,924 | — | 31 Mar 2026 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.87%
|
1,729,102
|
$162,743,080 | — | 31 Mar 2026 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.87%
|
1,717,978
|
$161,696,089 | — | 31 Mar 2026 | |
| Legal & General Group Plc |
13F
|
Company |
0.78%
|
1,543,188
|
$145,244,858 | — | 31 Mar 2026 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.78%
|
1,540,913
|
$145,030,732 | — | 31 Mar 2026 | |
| CAISSE DE DEPOT ET PLACEMENT DU QUEBEC |
13F
|
Company |
0.77%
|
1,520,486
|
$143,108,142 | — | 31 Mar 2026 | |
| FIRST TRUST ADVISORS LP |
13F
|
Company |
0.76%
|
1,500,792
|
$141,254,538 | — | 31 Mar 2026 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.64%
|
1,264,195
|
$118,986,033 | — | 31 Mar 2026 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.63%
|
1,253,138
|
$117,945,349 | — | 31 Mar 2026 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
0.61%
|
1,210,909
|
$113,970,755 | — | 31 Mar 2026 | |
| FMR LLC |
13F
|
Company |
0.59%
|
1,172,890
|
$110,392,397 | — | 31 Mar 2026 | |
| UBS Group AG |
13F
|
Company |
0.58%
|
1,138,004
|
$107,108,936 | — | 31 Mar 2026 | |
| AustralianSuper Pty Ltd |
13F
|
Company |
0.58%
|
1,137,143
|
$107,027,899 | — | 31 Mar 2026 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.53%
|
1,054,121
|
$99,212,000 | — | 31 Mar 2026 | |
| Amundi |
13F
|
Individual |
0.51%
|
1,003,969
|
$94,493,562 | — | 31 Mar 2026 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.5%
|
989,709
|
$93,151,426 | — | 31 Mar 2026 | |
| VANGUARD FIDUCIARY TRUST CO |
13F
|
Company |
0.48%
|
948,295
|
$89,253,525 | — | 31 Mar 2026 | |
| BNP Paribas Asset Management Holding S.A. |
13F
|
Company |
0.48%
|
938,848
|
$88,454,880 | — | 31 Mar 2026 | |
| Man Group plc |
13F
|
Company |
0.47%
|
930,171
|
$87,547,695 | — | 31 Mar 2026 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.46%
|
916,188
|
$84,787,753 | — | 31 Mar 2026 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.46%
|
915,527
|
$86,169,433 | — | 31 Mar 2026 | |
| SOUND SHORE MANAGEMENT INC /CT/ |
13F
|
Company |
0.39%
|
767,829
|
$72,268,065 | — | 31 Mar 2026 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.38%
|
751,856
|
$70,765,000 | — | 31 Mar 2026 | |
| SEI INVESTMENTS CO |
13F
|
Company |
0.36%
|
714,558
|
$67,254,073 | — | 31 Mar 2026 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.35%
|
693,785
|
$65,299,043 | — | 31 Mar 2026 |
Recent Insider Transactions by Companies or Individuals for INCYTE CORP
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Paul J. Clancy | INCY | Common Stock | Sale | -38.7% | $1,423,950 | $94.93 | -15,000 | 23,741 | 19 May 2026 | Direct |
| Paul J. Clancy | INCY | Common Stock | Options Exercise | 63.2% | 15,000 | 38,741 | 19 May 2026 | Direct | ||
| Paul J. Clancy | INCY | Non-Qualified Stock Option (right to buy) | Options Exercise | -100% | -15,000 | 0 | 19 May 2026 | Direct | ||
| BAKER BROS. ADVISORS LP | INCY | Common Stock | Options Exercise | 0.11% | 30,000 | 28,203,718 | 08 May 2026 | See Footnotes | ||
| BAKER BROS. ADVISORS LP | INCY | Common Stock | Options Exercise | 0.11% | 30,000 | 28,203,718 | 08 May 2026 | See Footnotes | ||
| Baker Bros. Advisors Lp | INCY | Common Stock | Options Exercise | 0.11% | 30,000 | 28,203,718 | 08 May 2026 | See Footnotes | ||
| Baker Bros. Advisors Lp | INCY | Common Stock | Options Exercise | 0.11% | 30,000 | 28,203,718 | 08 May 2026 | See Footnotes | ||
| Baker Bros. Advisors Lp | INCY | Common Stock | Options Exercise | 0.11% | 30,000 | 28,203,718 | 08 May 2026 | See Footnotes | ||
| Baker Bros. Advisors Lp | INCY | Common Stock | Options Exercise | 0.11% | 30,000 | 28,203,718 | 08 May 2026 | See Footnotes | ||
| BAKER BROS. ADVISORS LP | INCY | Non-Qualified Stock Options | Options Exercise | -100% | -30,000 | 0 | 08 May 2026 | See Footnotes | ||
| BAKER BROS. ADVISORS LP | INCY | Non-Qualified Stock Options | Options Exercise | -100% | -30,000 | 0 | 08 May 2026 | See Footnotes | ||
| Baker Bros. Advisors Lp | INCY | Non-Qualified Stock Options | Options Exercise | -100% | -30,000 | 0 | 08 May 2026 | See Footnotes | ||
| Baker Bros. Advisors Lp | INCY | Non-Qualified Stock Options | Options Exercise | -100% | -30,000 | 0 | 08 May 2026 | See Footnotes | ||
| Baker Bros. Advisors Lp | INCY | Non-Qualified Stock Options | Options Exercise | -100% | -30,000 | 0 | 08 May 2026 | See Footnotes | ||
| Baker Bros. Advisors Lp | INCY | Non-Qualified Stock Options | Options Exercise | -100% | -30,000 | 0 | 08 May 2026 | See Footnotes | ||
| Steven H. Stein | INCY | Common Stock | Award | 129% | 44,124 | 78,327 | 06 May 2026 | Direct | ||
| Pablo J. Cagnoni | INCY | Common Stock | Award | 13.4% | 31,517 | 266,317 | 06 May 2026 | Direct | ||
| Suketu Upadhyay | INCY | Common Stock | Award | 26,343 | 26,343 | 04 May 2026 | Direct | |||
| Suketu Upadhyay | INCY | Performance Shares | Award | 100% | 13,171 | 26,342 | 04 May 2026 | Direct | ||
| Suketu Upadhyay | INCY | Employee Stock Option (right to buy) | Award | 38,429 | 38,429 | 04 May 2026 | Direct | |||
| Pablo J. Cagnoni | INCY | Common Stock | Sale | -6.63% | $1,801,366 | $96.50 | -18,667 | 262,692 | 17 Apr 2026 | Direct |
| Pablo J. Cagnoni | INCY | Common Stock | Options Exercise | 7.11% | 18,667 | 281,359 | 17 Apr 2026 | Direct | ||
| Pablo J. Cagnoni | INCY | Employee Stock Option (right to buy) | Options Exercise | -41% | -18,667 | 26,833 | 17 Apr 2026 | Direct | ||
| William Meury | INCY | Common Stock | Options Exercise | 346.2% | 125,000 | 161,101 | 15 Apr 2026 | Direct | ||
| Pablo J. Cagnoni | INCY | Common Stock | Award | 11.9% | 27,892 | 262,692 | 15 Apr 2026 | Direct | ||
| Steven H. Stein | INCY | Common Stock | Award | 114.2% | 39,049 | 73,252 | 15 Apr 2026 | Direct | ||
| BAKER BROS. ADVISORS LP | INCY | Common Stock | Award | 842 | 28,188,718 | 31 Mar 2026 | See Footnotes | |||
| BAKER BROS. ADVISORS LP | INCY | Common Stock | Award | 842 | 28,188,718 | 31 Mar 2026 | See Footnotes | |||
| Baker Bros. Advisors Lp | INCY | Common Stock | Award | 842 | 28,188,718 | 31 Mar 2026 | See Footnotes | |||
| Baker Bros. Advisors Lp | INCY | Common Stock | Award | 842 | 28,188,718 | 31 Mar 2026 | See Footnotes | |||
| Baker Bros. Advisors Lp | INCY | Common Stock | Award | 842 | 28,188,718 | 31 Mar 2026 | See Footnotes | |||
| Baker Bros. Advisors Lp | INCY | Common Stock | Award | 842 | 28,188,718 | 31 Mar 2026 | See Footnotes | |||
| Edmund Harrigan | INCY | Common Stock | Award | 1.29% | 269 | 21,122 | 31 Mar 2026 | Direct | ||
| Paul J. Clancy | INCY | Common Stock | Award | 1.13% | 265 | 23,741 | 31 Mar 2026 | Direct | ||
| Matteo Trotta | INCY | Common Stock | Tax liability | -3.48% | -537 | 14,882 | 25 Mar 2026 | Direct | ||
| Pablo J. Cagnoni | INCY | Common Stock | Sale | -7.36% | $1,759,178 | $94.24 | -18,667 | 234,800 | 17 Mar 2026 | Direct |
| Pablo J. Cagnoni | INCY | Common Stock | Options Exercise | 7.95% | 18,667 | 253,467 | 17 Mar 2026 | Direct | ||
| Pablo J. Cagnoni | INCY | Employee Stock Option (right to buy) | Options Exercise | -67.2% | -18,667 | 9,102 | 17 Mar 2026 | Direct | ||
| Pablo J. Cagnoni | INCY | Common Stock | Sale | -7.37% | $1,883,788 | $100.91 | -18,668 | 234,800 | 19 Feb 2026 | Direct |
| Pablo J. Cagnoni | INCY | Common Stock | Options Exercise | 7.95% | 18,668 | 253,468 | 19 Feb 2026 | Direct | ||
| Pablo J. Cagnoni | INCY | Employee Stock Option (right to buy) | Options Exercise | -72.2% | -18,668 | 7,182 | 19 Feb 2026 | Direct | ||
| Lee Heeson | INCY | Common Stock | Tax liability | -0.29% | -111 | 38,041 | 02 Feb 2026 | Direct | ||
| Michael James Morrissey | INCY | Common Stock | Tax liability | -0.54% | -185 | 34,065 | 02 Feb 2026 | Direct | ||
| Michael James Morrissey | INCY | Common Stock | Tax liability | -1.24% | -429 | 34,250 | 20 Jan 2026 | Direct | ||
| Lee Heeson | INCY | Common Stock | Award | 30.5% | 8,911 | 38,152 | 16 Jan 2026 | Direct | ||
| Pablo J. Cagnoni | INCY | Employee Stock Option (right to buy) | Award | 28,475 | 28,475 | 16 Jan 2026 | Direct | |||
| Steven H. Stein | INCY | Employee Stock Option (right to buy) | Award | 19,932 | 19,932 | 16 Jan 2026 | Direct | |||
| Mohamed Khairie Issa | INCY | Employee Stock Option (right to buy) | Award | 14,237 | 14,237 | 16 Jan 2026 | Direct | |||
| Matteo Trotta | INCY | Employee Stock Option (right to buy) | Award | 8,542 | 8,542 | 16 Jan 2026 | Direct | |||
| Thomas Tray | INCY | Employee Stock Option (right to buy) | Award | 2,425 | 2,425 | 16 Jan 2026 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.